Guardant Health, Inc.
https://www.guardanthealth.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Guardant Health, Inc.
Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
Minute Insight: Hedera DX Completes €14m Raise To Fund ML-Backed Liquid Biopsy Tech
Hedera DX’s liquid biopsy test uses machine learning to recommend drugs to patients based on a tumor’s circulating DNA profile.
Company Information
- Industry
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Other Names / Subsidiaries
-
- Guardant
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice